

Technology Advisory Committee C Interests Register

Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3740]

Publication Date: 25 August 2021

There were no declarations of interests for this appraisal.